- Home
- HLP vs AVTX Comparison
HLP vs AVTX Comparison
Compare HLP & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- AVTX
- Stock Information
- Founded
- HLP 2021
- AVTX 2011
- Country
- HLP China
- AVTX United States
- Employees
- HLP N/A
- AVTX N/A
- Industry
- HLP Industrial Machinery/Components
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- AVTX Health Care
- Exchange
- HLP Nasdaq
- AVTX Nasdaq
- Market Cap
- HLP 96.2M
- AVTX 88.4M
- IPO Year
- HLP 2023
- AVTX 2015
- Fundamental
- Price
- HLP $1.33
- AVTX $8.44
- Analyst Decision
- HLP
- AVTX Strong Buy
- Analyst Count
- HLP 0
- AVTX 4
- Target Price
- HLP N/A
- AVTX $33.00
- AVG Volume (30 Days)
- HLP 65.4K
- AVTX 37.8K
- Earning Date
- HLP 03-19-2025
- AVTX 03-28-2025
- Dividend Yield
- HLP N/A
- AVTX N/A
- EPS Growth
- HLP N/A
- AVTX N/A
- EPS
- HLP N/A
- AVTX N/A
- Revenue
- HLP $14,045,084.00
- AVTX $820,000.00
- Revenue This Year
- HLP N/A
- AVTX N/A
- Revenue Next Year
- HLP N/A
- AVTX N/A
- P/E Ratio
- HLP N/A
- AVTX N/A
- Revenue Growth
- HLP N/A
- AVTX N/A
- 52 Week Low
- HLP $0.99
- AVTX $4.24
- 52 Week High
- HLP $2.25
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- HLP 50.48
- AVTX 57.77
- Support Level
- HLP $1.32
- AVTX $6.81
- Resistance Level
- HLP $1.41
- AVTX $8.00
- Average True Range (ATR)
- HLP 0.08
- AVTX 0.56
- MACD
- HLP 0.01
- AVTX 0.03
- Stochastic Oscillator
- HLP 45.16
- AVTX 81.99
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).